0.3, 1.0, or 1.5 mg/kg, IV once a week for 4 weeks, with follow-up to 16 weeks
= 96
Significant differences in DAS28 change between placebo and MOR-103: None, weeks 4 through 10, weeks 4 through 6
ACR at week 4, 1.0 mg/kg versus placebo ACR20: 68.2% versus 7.4% () ACR50: 22.7% versus 3.7% (ns) ACR70: 4.5% versus 0.0% (ns)
SC: subcutaneous injection; IV: intravenous injection; MTX: methotrexate; DAS28: 28-joint disease activity score; ACR20: American College of Rheumatology 20% response rate; ACR50: American College of Rheumatology 50% response rate; ACR70: American College of Rheumatology 70% response rate.